Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00497770 · ClinicalTrials.gov registry record
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 434
- Enrollment target
NCT00497770 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 434 participants.
The verdict
NCT00497770 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 434 participants
- Enrollment target
Study Summary
This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 434 participants |
| Start Date | 2007-02 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00497770
The ClinicalTrials.gov registry entry for NCT00497770 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 434 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00497770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00497770 about?
NCT00497770 is a clinical study titled "An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed". This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.
What is the current status of trial NCT00497770?
This trial is currently completed. The enrollment target is 434 participants. The study started on 2007-02. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00497770?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00497770?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.